Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Solid Meal Clear all
Completed Not applicable Interventional

Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery

NCT01938469
View directory record Official record
Conditions
Gastric Bypass Surgery, Obesity
Interventions
Liquid Meal, Solid Meal
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

NCT01149720
View directory record Official record
Conditions
Solid Tumors
Interventions
Tivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D, oral
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Santa Monica, California • Fort Myers, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

NCT04834778
View directory record Official record
Conditions
Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
Interventions
HC-5404-FU
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Detroit, Michigan • Saint Paul, Minnesota • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Results available

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

NCT02783300
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3326595, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Denver, Colorado • Miami, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Not applicable Interventional

Open Trial Obesity CHANGE Program ASD

NCT03047018
View directory record Official record
Conditions
Autism Spectrum Disorder, Obesity
Interventions
The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program
Behavioral
Lead sponsor
Emory University
Other
Eligibility
5 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 22, 2026, 1:16 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults

NCT03031132
View directory record Official record
Conditions
Appetite and General Nutritional Disorders
Interventions
HP-Beverage Breakfast, HP-Solid Breakfast, Breakfast Skipping
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
20 Years to 32 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of Orally Administered BPM31510 in Healthy Subjects

NCT02486055
View directory record Official record
Conditions
Healthy
Interventions
BPM31510 Oral Nanosuspension 4%
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 22, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

NCT06075953
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
28
States / cities
Berkeley, California • Duarte, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Study of Regorafenib and Sildenafil for Advanced Solid Tumors

NCT02466802
View directory record Official record
Conditions
Solid Tumor
Interventions
Regorafenib, Sildenafil Citrate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Studying Different Formulations of SR13668 in Healthy Volunteers

NCT00896207
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
Akt inhibitor SR13668
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 62 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 22, 2026, 1:16 PM EDT
Terminated Phase 1 Interventional

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

NCT05083481
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MENU Study: Online Experiment

NCT06909019
View directory record Official record
Conditions
Food Selection
Interventions
Control (QR) Labels, Low Climate Impact Labels, High Climate Impact Labels, Traffic Light Labels, Climate Grade Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
6,294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 22, 2026, 1:16 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects

NCT01677338
View directory record Official record
Conditions
Dyspeptic Subjects
Interventions
13C-uracil, 99mTc sulfur colloid
Drug
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Orlando, Florida • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

NCT02559570
View directory record Official record
Conditions
Functional Constipation in Children Ages 6-17 Years
Interventions
Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
60
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 22, 2026, 1:16 PM EDT
Completed No phase listed Observational

Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders

NCT01137240
View directory record Official record
Conditions
Gastrointestinal Dysfunction, Mitochondrial Disorders
Interventions
gastric emptying scan
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 22, 2026, 1:16 PM EDT
Not listed Phase 1 Interventional

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

NCT02500199
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Solid Tumors, NSCLC
Interventions
Pyrotinib
Drug
Lead sponsor
Hengrui Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Orange, California • Sacramento, California • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 in Healthy Subjects

NCT01450098
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2484595 Reference Formulation (RF), LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 22, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

NCT04469530
View directory record Official record
Conditions
Solid Tumor
Interventions
Sirolimus, Cyclophosphamide, Etoposide, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

NCT01017198
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BIIB021 and Food, BIIB0121 and Antacid
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Encinitas, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2013 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver

NCT00742911
View directory record Official record
Conditions
Cancer
Interventions
Disulfiram, Copper Gluconate
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 22, 2026, 1:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

NCT04209595
View directory record Official record
Conditions
Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
Interventions
PLX038, Rucaparib, Ondansetron
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 22, 2026, 1:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

NCT05204862
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
TU2218, Anti-PD-1 antibody
Drug
Lead sponsor
TiumBio Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 22, 2026, 1:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

NCT01311713
View directory record Official record
Conditions
Solid Tumors
Interventions
CEP-9722
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Aurora, Colorado • Detroit, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 22, 2026, 1:16 PM EDT